Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.
More Stories
GM expects 2025 earnings to be similar to this year’s despite industry headwinds
The Detroit automaker's targeted adjusted earnings before interest and taxes this year is between $13 billion and $15 billion, or...
PepsiCo trims revenue outlook as North American snacking, key international markets lag
PepsiCo lowered its full-year outlook for organic revenue but reiterated its forecast for its earnings growth.
Samsung posts disappointing third-quarter profit guidance as it grapples with AI chips
Samsung posts worse-than-expected guidance for third quarter
Rivian shares fall after EV maker slashes production forecast, misses Q3 delivery expectations
Rivian produced 13,157 vehicles at its manufacturing facility in Normal, Illinois and delivered 10,018 vehicles during the same period.
Modelo brewer Constellation falls despite an earnings beat. Here’s why we’re not concerned
Constellation Brands on Thursday delivered a solid earnings report and set the stage for an anchor to be raised in...
Levi Strauss trims guidance as it weighs sale of Dockers business
Denim-maker Levi Strauss is looking to sell its Dockers brand as the khaki maker drags down the company's overall performance.